Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
about
Anticholinergics for urinary symptoms in multiple sclerosisAnticholinergics for urinary symptoms in multiple sclerosisMedical management of neurogenic bladder with oral therapyNeurogenic bladder in spinal cord injury patientsDose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinenceEfficacy, tolerability, and safety of oxybutynin chloride in pediatric neurogenic bladder with spinal dysraphism: a retrospective, multicenter, observational studySolifenacin in multiple sclerosis patients with overactive bladder: a prospective study.Current management of neurogenic bladder in patients with MS.Management of lower urinary tract dysfunction in patients with neurological disordersMaximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction.An integrative review of standardized clinical evaluation tool utilization in anticholinergic drug trials for neurogenic lower urinary tract dysfunction.Treatment of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelinesBladder symptoms in multiple sclerosis: a review of pathophysiology and management.Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management.The management of adolescents with neurogenic urinary tract and bowel dysfunction.Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics.Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders.Urodynamic Management of Neurogenic Bladder in Spinal Cord Injury.Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study.Characteristics of neurogenic voiding dysfunction in cerebellar stroke: a cross-sectional, retrospective video urodynamic study.[Neuro-urological dysfunction of the lower urinary tract in CNS diseases: pathophysiology, epidemiology, and treatment options].Multiple sclerosis and continence issues: an exploratory study.An effective day case treatment combination for refractory neuropathic mixed incontinence.Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study.Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder.A complex series of events in a patient with sacral anterior root stimulator (SARS).Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury.The Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis.
P2860
Q24187386-662416A6-55BE-4E93-8241-C3FF8411CCFCQ24241666-B9191F54-CD32-467C-904D-45C62083A5BCQ26767313-9E1E50D3-0FD9-4E56-85C7-498191059490Q28087196-5D821D7F-A839-4A5F-9C75-93CE5925482CQ33692394-EA1D78C4-5FF5-43D4-B173-A6DE470E0F61Q34698269-019613CD-38D8-4E2A-9057-3B4784B7016FQ35042588-B20B0A56-89B5-4BAF-8E0B-D5F13EBC92C0Q35776873-DF4E3591-CBAE-4313-B1EC-49F8C3F19445Q36284726-494B58E9-C484-495A-B399-14ACD9C1A3ADQ36815273-EB98C498-05AF-4555-907D-49B7DE53414FQ37484824-852EAD78-6DCD-442B-8699-BF9BDB5F0B48Q37641104-FACA6390-D89F-4B79-8F20-5CA03D6C6A94Q37720749-C1FD4936-77B1-4D1C-9AFB-5096F51F8E73Q37766886-4520D27C-3C21-4C30-91D0-1C6C239D6F08Q37941525-68CA4F4B-FB6B-476E-BF5F-AC882DA6B355Q37998353-5A8FF963-3A7C-4096-B376-1DED931ECE09Q38112554-2035FE04-E7EB-4E40-8B80-04126DA92517Q38231743-90995936-7E92-43B1-B4FA-295CAFE3BF7AQ38391474-79EBEDF0-9107-4AA8-B633-C5655E7A0068Q39297920-48464160-B36C-432F-8927-6639E35B9310Q40161984-E2BC4598-64A5-4591-A759-B65772E543FBQ43696467-43AA70A3-BF1E-4CBC-969E-F49410C6588FQ44788209-05847BA8-957D-45AB-BE2D-2173EB2E55BFQ46516967-2CC69830-B66C-459D-9D12-55D65E7E19D9Q47845516-AD7BF905-A3E1-467F-9FA0-FACDC1E4E65FQ48432214-8FEADA8B-F718-4F21-802D-1DB143E8CE61Q51029994-1FC3C956-0F01-417A-B87F-07D95E382172Q51589293-378E5062-6ED2-42A9-A8AC-18725294E9EDQ51732450-D045F8AD-1AF9-45D3-A747-1AD26E2F5C00Q53236412-18596526-8F57-4148-A787-8D93715DD442Q55486735-A5910E73-333E-4D48-B77E-1C02829346F1
P2860
Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
@en
Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
@nl
type
label
Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
@en
Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
@nl
prefLabel
Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
@en
Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
@nl
P2093
P1476
Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
@en
P2093
Ankur S Patel
Janet R Erickson
Macrina Xavier
Margie O'Leary
Michael B Chancellor
Nelson Bennett
P304
P356
10.1097/01.JU.0000103274.38694.B1
P407
P433
P577
2004-02-01T00:00:00Z